FormalPara Key Summary Points

Unlike vaccine-derived immunity that develops over time, administration of neutralizing monoclonal antibodies (mAbs) is an immediate and passive immunotherapy that reduces viral load and holds the potential to control disease progression and prevent emergency room visits, hospitalizations, and death.

This report describes the development of bamlanivimab and etesevimab, IgG1 human neutralizing mAbs that bind to distinct yet overlapping epitopes within the receptor binding domain of the SARS-CoV-2 spike protein, and the role of bamlanivimab and etesevimab for the treatment of patients with mild-to-moderate COVID-19 illness within 10 days of symptom onset and at high risk for progressing to severe COVID-19 and/or hospitalization.

Bamlanivimab alone and together with etesevimab hold emergency use authorizations in several countries globally, with countries increasingly transitioning to the use of bamlanivimab and etesevimab together and other authorized mAbs on the basis of their evolving variant landscape, regulatory authorizations, and access to drugs.

This report provides evidence-based practical guidance and rationales for administering bamlanivimab and etesevimab together and addresses the most frequent clinical questions received from health care professionals and patients around indicated population, dose, use with other medications and vaccines, duration of protection, and variants.

This report also discusses the practical learnings and the most recent real-world evidence detailing the adapted clinical care procedures and facilities that have been implemented to rapidly operationalize infusions of these mAbs.

Introduction

Prophylactic and therapeutic treatments are being developed to target the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is responsible for the ongoing coronavirus disease 2019 (COVID-19) global pandemic [1]. The spike protein of SARS-CoV-2 has become the focal point for many targeted treatment approaches, including neutralizing monoclonal antibodies (mAbs), which are recombinant proteins that can be used as a type of passive immunotherapy to minimize virulence [2]. While vaccines remain the primary option for COVID-19 prevention [3, 4], mAbs are an effective treatment for those already infected, as well as having the potential to prevent infection in those already exposed to SARS-CoV-2, which can be of particular benefit to certain high-risk subpopulations [5,6,7,8]. Extensive reviews have been published on the role of mAbs in the COVID-19 treatment landscape with a focus on the mAbs that first received emergency use authorization (EUA) and their mechanism of action [5, 9]. Bamlanivimab became the first authorized therapeutic neutralizing mAb specifically developed to treat COVID-19 and was subsequently combined with a second mAb, etesevimab [6, 10, 11]. Specifically, bamlanivimab and etesevimab are neutralizing immunoglobulin G1 (IgG1) mAbs that bind to distinct yet overlapping epitopes within the receptor binding domain (RBD) of the spike protein, thereby minimizing the potential for treatment-emergent resistant variants [12, 13]. Other neutralizing mAbs have also subsequently been granted EUAs, thus providing further evidence that this class of treatment is an effective targeted intervention for patients at risk [14, 15].

This review presents an overview of the treatment development of bamlanivimab and etesevimab together, provides the rationales for the clinical utility for patients, and examines the clinical practicalities of their administration in the rapidly changing disease landscape. The intention of this review is to address the most frequently received clinical questions from health care professionals (HCPs) and patients around the indicated population, dose, use with other medications and vaccines, duration of protection, and variants. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

This narrative review provides a summary of the main evidence-based practical guidance and rationales for administering bamlanivimab and etesevimab together and addresses the most frequently received clinical questions from HCPs and patients in six sections. The first section provides an overview of the treatment development process of bamlanivimab and etesevimab and is followed by a detailed review of the indicated population and the key clinical outcomes supporting the practical guidelines provided in the EUA factsheets. The subsequent section provides the evidence and rationales informing the infusion doses and timeframes. This section is followed by a brief review of the practical learnings gathered from the most recent real-world evidence of adapted clinical care procedures and facilities to rapidly operationalize infusions of these mAbs. The fifth section reviews the available information on concomitant medications and vaccines in relation to these mAbs. Finally, the evolving variant landscape is assessed and the implications for mAb treatments are discussed.

Overview of Bamlanivimab and Etesevimab Treatment Development

The rapid development of bamlanivimab and etesevimab was contingent on the platform phase 2/3 trial entitled BLAZE-1, an adaptive multiarm, multistage trial designed to allow evaluation of multiple interventions. An overview of the BLAZE-1 study design is provided in Fig. 1. In the phase 2 portion of BLAZE-1, bamlanivimab was tested alone at three different doses (arms 2–4: 700, 2800, and 7000 mg, respectively) and in combination with etesevimab (arm 6: 2800/2800 mg). Learnings from phase 2 were subsequently applied in the phase 3 portion of BLAZE-1 where only patients at higher risk of developing severe COVID-19 were randomized to receive placebo or bamlanivimab and etesevimab together at two different dose combinations (arm 7: 2800/2800; arm 9: 700/1400 mg). Reduction in viral load, COVID-19-related hospitalizations and deaths, as well as symptomatology resolution were key outcomes and have been published elsewhere [13]. Table 1 summarizes the key efficacy results that further substantiated the suitability of bamlanivimab alone or together with etesevimab as treatment options for high-risk patients [6, 13, 16].

Fig. 1
figure 1

BLAZE-1 phase 2/3 study design to evaluate the efficacy of bamlanivimab alone and together with etesevimab in ambulatory participants with mild to moderate COVID-19 illness. Doses of bamlanivimab and etesevimab presented in brackets. N number of patients in cohort

Full size image
Table 1 Key clinical outcomes from the phase 2 and phase 3 portions of the BLAZE-1 trial of bamlanivimab and etesevimab together for patients with mild-to-moderate COVID-19
Full size table

The BLAZE-1 trial enrolled patients who had not been hospitalized, but had one or more mild or moderate COVID-19 symptoms [17]. Ambulatory patients (with mild-to-moderate COVID-19) that were at a higher risk of progressing to severe COVID-19 (based on the Centers for Disease Control and Prevention (CDC) guidance [18]) were infused within 3 days of providing their first positive SARS-CoV-2 test sample. The median duration of symptoms was 4 days prior to infusion [13] and based on clinical practice and US Food and Drug Administration (FDA) guidance the factsheet indicates patients should be treated within 10 days of symptom onset [19]. Mild-to-moderate COVID-19 disease equates to a score of 1–4 on the World Health Organization (WHO) clinical progression scale that provides a measure of illness severity [20]. The majority of patients (77%) enrolled to BLAZE-1 were classified as having mild COVID-19 defined by the FDA as symptoms of mild illness that could include cough, fever, sore throat, headache, malaise, muscle pain, diarrhea, nausea, vomiting, and no shortness of breath or dyspnea (per the protocol, patients with a saturation of peripheral oxygen (SpO2) ≥ 93% or PaO2/FiO2 > 300 were included), and no clinical signs indicative of moderate or severe, or critical severity [17].

As there is a risk of infusion reaction and hypersensitivity (including anaphylaxis) with any monoclonal agent, all trial participants were monitored closely during the intravenous (IV) infusion period and for at least 2 h following infusion completion [6]. On the basis of safety data accumulated since clinical studies began, monitoring following infusion completion has been reduced to approximately 1 h. From phase 2 data, the most frequently reported adverse events reported in patients receiving bamlanivimab and etesevimab together (2800/2800 mg) or placebo were nausea (3.6% and 3.8%, respectively), and diarrhea (0.9% and 4.5%, respectively) [13]. The percentage of serious adverse events was 0% in the bamlanivimab monotherapy cohort compared with 0.9% in the bamlanivimab and etesevimab together cohort and 0.6% in the placebo cohort. Of the approximately 4000 subjects who have received bamlanivimab (either alone or with etesevimab) during BLAZE-1 and other clinical trials, approximately 800 subjects have received bamlanivimab and etesevimab together at the authorized doses (700/1400 mg) during the phase 3 portion. Of the patients who have received bamlanivimab and etesevimab together at the authorized doses or higher, 1.1% have had an infusion-related reaction and there has only been a single case (0.07%) of anaphylaxis [19].

Total evidence gathered from these clinical trials [6, 13] and supported by preclinical data [21] culminated in an EUA granted by the FDA in November 2020 for bamlanivimab alone [22] and subsequently for bamlanivimab and etesevimab together in February 2021 [19], which has also received a positive scientific opinion in the European Union (EU) from the committee for Medicinal Products for Human Use [23]. At the request of Eli Lilly and Company, the EUA for bamlanivimab alone has since been revoked by the FDA as of April 16, 2021, in response to the emergence of certain variants in the USA [15, 19, 24]. As of June 2021, three neutralizing monoclonal antibody (mAb) therapies (casirivimab and imdevimab together, sotrovimab alone, and bamlanivimab and etesevimab together) have EUAs in the USA [14, 15, 19]. Outside of the USA, bamlanivimab alone and bamlanivimab plus etesevimab hold EUAs, although these countries are transitioning to the use of bamlanivimab and etesevimab together and other authorized mAbs on the basis of their evolving variant landscape, regulatory authorizations, and access to drugs [15, 24]. Context and rationales for the guidance on the role of mAbs in the rapidly evolving variant landscape are provided herein to assist HCPs in making informed decisions. The key development milestones and clinical trials that lead to treatment authorizations and the increasing availability of these COVID-19 treatment options are illustrated in Fig. 2.

Fig. 2
figure 2

A timeline of the clinical development of bamlanivimab alone and together with etesevimab, including key milestones. EUA emergency use authorization, EMA European Medicines Agency, CHMP EMA’s human medicines committee, HCP health care providers

Full size image

High-Risk Populations and Key Clinical Outcomes

This section explores the patient eligibility criteria for bamlanivimab and etesevimab treatment based on the most updated US factsheet and demonstrates the continual need to adapt the key operational practicalities on the basis of the latest clinical outcomes. An overview of the indicated population is represented in Fig. 3 and key clinical outcomes supporting these guidelines are provided in Table 1.

Fig. 3
figure 3

Overview of high-risk criteria used to determine patient eligibility for treatment of mild-to-moderate COVID-19 with bamlanivimab and etesevimab together

Full size image

There is growing evidence that indicates COVID-19 mortality and hospitalization rates are higher in patients with certain risk factors, including older age, increased body mass index (BMI), or certain comorbidities including diabetes, chronic kidney disease, chronic lung disease, and some neurological disorders, among others [18, 25,26,27,28,29,30,31]. Recently updated guidance provided by the CDC indicates other factors may also increase the risk of severe illness from COVID-19 including pregnancy, substance use disorders, smoking, and other underlying medical conditions [32]. Ultimately, health care providers should consider the benefit-to-risk ratio for an individual patient [19].

On the basis of clinical trials, bamlanivimab and etesevimab together have been identified as having an acceptable benefit-to-risk ratio for patients who are deemed to be at higher risk for progressing to severe COVID-19 and/or hospitalization [13, 19]. “High risk” in the BLAZE trials was defined by the criteria derived from guidance originally provided by the CDC [18]. These criteria included an age of 65 years or older, a BMI of 35 kg/m2 or more, or at least one relevant coexisting illness or concomitant medication. In the phase 2 portion of the BLAZE-1 trial, 67% of patients (N = 577) enrolled met at least one criteria for high risk; in the phase 3 portion of the BLAZE-1 trial, 100% of patients (N = 1035) enrolled met the criteria for high risk [16]. In the phase 3 portion, the most common baseline high-risk comorbidities were age 65 years or older (31.2%), BMI of 25 kg/m2 or more (86.4%), hypertension (33.9%), and type 2 diabetes mellitus (18.8%). Patients with chronic kidney disease, immunosuppressive treatments, immunosuppressive disease, chronic obstructive pulmonary disease, malignancies, and others were also included (each representing less than 5%).

Consistently, there was a significant relative risk reduction (RRR) for COVID-related hospitalization (at least 24 h of acute care) or death for patients who were treated with bamlanivimab and etesevimab across both phase 2 and phase 3 portions of BLAZE-1 compared with patients who received placebo. In the phase 2 portion of BLAZE-1, the absolute risk reduction (ARR) and RRR for the entire cohort treated with bamlanivimab and etesevimab (2800/2800; N = 112) were 5% and 100%, respectively, compared with placebo and the number needed to treat (NNT) was 22. For the high-risk patient cohort treated with bamlanivimab and etesevimab (2800/2800; N = 38) the ARR and RRR were 9% and 100%, respectively, compared with placebo and the NNT was 11. In the phase 3 portion of the BLAZE-1 trial, the ARR and RRR for the entire high-risk patient cohort treated with bamlanivimab and etesevimab together (2800/2800 mg; N = 518) were 5% and 70%, respectively, compared with placebo and the NNT was 21. For the high-risk patients treated with bamlanivimab and etesevimab together (700/1400 mg; N = 511) the RRR was 87% compared with placebo. These data support the hypothesis that early intervention with bamlanivimab together with etesevimab greatly improves the clinical outcomes for high-risk ambulatory patients.

Pregnant or breastfeeding women were excluded from the clinical trials and therefore there are currently insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Therefore, bamlanivimab and etesevimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus. From May 1, 2020 to February 26, 2021, 11 pregnancies were reported spontaneously in the bamlanivimab and etesevimab clinical trials, three of which were reported in patients treated with bamlanivimab and etesevimab together [33]. To date, there are no available data on the presence of bamlanivimab or etesevimab in human milk, the effects on the breastfed infant, or the effects on milk production.

Whilst there are limited data for the treatment of bamlanivimab and etesevimab together in pediatrics, the EUA recommendations were determined by the extrapolation of adult clinical trials based on weight models of outcomes. Although initial inclusion criteria for BLAZE-1 specified that patients were 18 years or older, the age has since been reduced to 12 years or older and 1% of patients in the phase 3 portion (2800/2800 mg) were 12–17 years of age (inclusive) [34]. Children younger than 14 years old appear to be less commonly affected by COVID-19 disease than adults, but the incidence increases with increasing age [35,36,37,38,39]. Despite reports of severe COVID-related illness, including fatality, in children, most children appear to be asymptomatic or report mild or moderate disease [40]. However, children with underlying medical conditions are at greater risk for severe COVID-19 disease compared with children without underlying conditions [38, 41].

Rationales for Infusion Dose and Timeframe

The authorized doses of bamlanivimab and etesevimab together (700/1400 mg) were informed by pharmacokinetic (PK) and pharmacodynamic (PD) modeling, and antibody-viral dynamic modeling and simulations. The PD data showed a flat exposure–response relationship for efficacy within this dose range and the PK profile of bamlanivimab was also found to be linear and dose-proportional between 700 and 7000 mg following a single IV administration [19]. In the phase 2 portion of BLAZE-1, pooled patients receiving any dose level of bamlanivimab (700, 2800, 7000 mg) had a decreased frequency of ER visits and hospitalizations compared to patients that received placebo [6]. On the basis of these data, and to maximize the number of patients that could be treated with existing drug supply, the lowest dose of 700 mg was selected for EUAs. To provide coverage of the different, but overlapping, epitopes on SARS-CoV-2 RBD sites for bamlanivimab and etesevimab together, the dose selection rationale for each single mAb administered together was the same as for a single mAb administered alone. On the basis of in vitro potency differences and PK/PD modeling, an approximately twofold higher etesevimab dose to bamlanivimab dose was judged to achieve maximum therapeutic response to reduce viral load, and sustained concentration above the respective IC90 of viral neutralization for at least 28 days in 90% of the patient population. Bamlanivimab with etesevimab (700/1400 mg) also had similar antiviral activity compared with the higher dose combination (2800/2800 mg) in the phase 2 portion of BLAZE-1 [42]. On the basis of these data, the lowest tested dose of 700 mg of bamlanivimab together with a twofold higher dose of 1400 mg of etesevimab are now authorized [19].

One of the key learnings is that bamlanivimab alone or together with etesevimab should be administered as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset. The rationale for this timeframe is based primarily on the supportive efficacy and safety data collected for patients with mild-to-moderate COVID-19 symptoms during the BLAZE-1 trial, as opposed to patients who had already progressed to severe disease symptoms or had been hospitalized. Additionally, the ACTIV-3 trial undertaken by the National Institute of Allergy and Infectious Diseases (NIAID) has informed that neutralizing mAbs, on top of standard of care, might not be effective in the later stages of the disease when illness severity is driven primarily by the immune response, rather than active viral replication. Therefore, the use of bamlanivimab and etesevimab is limited to patients who are not hospitalized for COVID-19, nor require oxygen for COVID-19.

Real-World Experiences

As of April 28, 2021, the US Department of Health and Human Services reported that over 450,000 patients have received mAbs in the USA [43]. Despite the logistical challenge of administering IV infusions of mAbs to ambulatory, at-risk patients with COVID-19, there is growing independently published, real-world evidence that describes how different systems have operationalized the infusions based on multidisciplinary efforts and the repurposing of outpatient facilities [44,45,46,47,48]. Flexible referral systems and forms to test and identify suitable patients, as well as the coordinated collection of electronic real-time data have been examples of innovative approaches some hospitals, long-term care facilities, and outpatient or community-based centers have adopted in record time [44,45,46,47,48].

Real-world data based on case or control studies demonstrate that these neutralizing mAbs significantly reduce hospitalizations and deaths, without posing significant risks [46, 48,49,50,51,52]. Limited preliminary data has also indicated similar benefit may also apply for the most vulnerable populations, such as those with organ transplants [51].

On the basis of clinical trials and emerging real-world learnings, organizations have been able to adapt their systems to maximize the administration of neutralizing mAbs to patients. Key aspects facilitating greater flexibility for HCPs administering bamlanivimab and etesevimab include the aseptic preparation of the infusions based on simple dilutions and the administration of the drugs using different infusion bag materials (polyvinylchloride (PVC) or polyethylene (PE)-lined PVC), bag sizes (50, 100, 150, or 250 mL), shortened infusion times (21-min infusion time when 50-mL infusion bag used), and pump or gravity infusion options [19]. There are also no hazardous risks associated with handling bamlanivimab and etesevimab and they can be stored for up to 7 h at room temperature or 24 h when refrigerated. In addition to these improvements, there is now a clearer understanding of monitoring requirements and how to handle potential adverse events (mainly mild to moderate infusion-related reactions). These factors have been essential to overcoming the challenges involved with treating patients with mAb treatments.

Concomitant Medications and Vaccines

Inclusion criteria in the BLAZE-1 trial permitted certain medications to be used prior to the study including antivirals, corticosteroids, and other therapeutic agents [6]. During the study, certain concomitant medications were permitted if they were considered part of the local standard of care at the time. Up to 34% patients from the phase 2 portion of the study (N = 577) took one or more concomitant medications, including lopinavir, ritonavir, chloroquine, hydroxychloroquine, and corticoids. Acetaminophen and ibuprofen were the most commonly taken medications (20% and 8%).

Convalescent COVID-19 plasma treatment prior to enrollment or during the study, participation in a previous SARS-CoV-2 vaccine study, or participation in a clinical study involving an investigational intervention within the last 30 days were not allowed per the exclusion criteria. Also, if a previous investigational intervention had a long half-life, then 5 half-lives or 30 days (whichever was longer) should have passed. Other exclusion criteria encompassed any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, would preclude participation in the study. Patients with moderate or severe hepatic impairment were also excluded, as evaluated with the criteria for hepatic dysfunction developed by the National Cancer Institute Organ Dysfunction Working Group [53]. Since there was no difference in the PK of bamlanivimab or etesevimab in patients with mild hepatic impairment compared with patients with normal hepatic function, no dosage adjustment is recommended in patients with mild hepatic impairment.

Concomitant use of medications with bamlanivimab and etesevimab is not contraindicated in the EUA as these mAbs are not renally excreted or metabolized by cytochrome P450 enzymes and therefore interactions are unlikely with concomitant medications. Data regarding the safety and efficacy of mAbs in patients with renal failure and patients receiving hemodialysis are limited, and most of the available information is based on case reports [54, 55]. As a result of the large size of the mAbs (146 kDa for bamlanivimab and 145 kDa for etesevimab), they are unlikely to be affected by renal impairment or to be removed by hemodialysis [22, 55]. Renal impairment and dialysis are not expected to impact the PK of bamlanivimab or etesevimab, and no dose adjustment is recommended in patients with renal impairment.

The BLAZE-1 trial excluded patients who had participated in a SARS-CoV-2 vaccine study; however, non-SARS-CoV-2 vaccinations were permitted prior to enrollment on the basis of standard of care or on a case-by-case basis following consultation with the sponsor [6]. Therefore, to date, there are no data available regarding the efficacy and safety of administration of a SARS-CoV-2 vaccine, or other vaccine, before or after receipt of bamlanivimab and etesevimab for the treatment of mild-to-moderate COVID-19. The mean apparent elimination half-life for bamlanivimab and etesevimab is 17.6 days and 25.1 days, respectively [19]. There is a theoretical risk that antibody administration may attenuate the endogenous immune response to SARS-CoV-2 and make patients more susceptible to reinfection [19].

For partially and fully vaccinated patients who subsequently develop COVID-19, prior receipt of a SARS-CoV-2 vaccine should not influence COVID-19 treatment decisions or the timing of such treatments [56, 57]. Since there are no safety and efficacy data with COVID-19 vaccines in people who have received mAbs, the CDC recommends the deferral of vaccination for 90 days following antibody treatment as a precautionary measure until further data become available. The rationale for a 90-day deferral is not based on clinical trials but on general assumptions that take into account the estimated half-life of such therapies and the premise that reinfection is uncommon for 90 days after initial infection [58].

Impact of Variants

The SARS-CoV-2 virus is composed of four structural proteins, of which the spike glycoprotein is critical for viral attachment, fusion, and entry and therefore is a key target for antibodies and vaccines. The RBD unit of the spike protein mediates viral entry by binding to the angiotensin-converting enzyme 2 on the host cell, which is a cell receptor expressed by lung, gastrointestinal (GI) tract, and nasal mucosa cells. Naturally occurring variants in viruses are common with some mutations altering binding affinity and infectivity.

In order to predict and monitor for antiviral resistance, preclinical research was used to characterize the functional binding and to evaluate potential emergent treatment-resistant variants in vitro. Ongoing clinical research and global surveillance utilize genotyping and phenotyping to gain knowledge of resistance-associated mutations and the mechanisms of action of resistance. Viral genomes are continuously sequenced and shared via the Global Science Initiative on Sharing All Influenza Data (GISAID) (https://www.gisaid.org/), facilitating the real-time monitoring of genomic variants across the world. Since November 2020, the CDC carries out regular genomic surveillance across different US states to track emerging variants that may impact the efficacy of bamlanivimab, etesevimab, and other mAbs [59]. However, variant reporting is complex and available data can vary across databases because of changing naming or categorization conventions or whether the date recorded relates to when a sample was first collected or first submitted to a database [60,61,62]. Current estimates suggest the SARS-CoV-2 evolution rate is more comparable to influenza than measles, with the virus continuously evolving to escape immunity and therefore may require annually updated vaccines [63]. Variants of concern (VOC) and variants of interest (VOI) have emerged and been identified by the WHO since January 2020 [64]. These VOCs have similar mutations that might impact transmission, virulence, and treatment response, such as D614G and mutations at K417N/T, L452R, E484K, or N501Y. Particular mutations in the SARS-CoV-2 RBD domain can impact the binding of mAbs and thereby affect their efficacy.

The potential for SARS-CoV-2 to escape neutralization under selective pressure of bamlanivimab and/or etesevimab was studied in vitro using serial passaging and RBD-directed evolution studies. Passaging studies identified potential escape mutations for bamlanivimab (F490S and S494P) and etesevimab (D420N and N460K). RBD-directed evolution studies identified potential escape mutations for bamlanivimab (E484K/Q, F490S, Q493R, and S494P) and etesevimab (D420N and N460K/S) [65]. Significantly, no mutations were identified using either method under the selective pressure of bamlanivimab and etesevimab together. Clinical data also supported the assessment that combining neutralizing mAbs that target distinct epitopes within the RBD may minimize viral neutralization escape [13].

On the basis of the latest variant data, the EUA for bamlanivimab alone has been revoked by the FDA as of April 16, 2021 following a request by Eli Lilly and Company [22]. This revocation triggered an acceleration towards supply and use of bamlanivimab and etesevimab together in the USA, as well as outside of the USA (OUS). Bamlanivimab and etesevimab have both been found to have decreased binding to the Beta (formally South African origin, B1.351) and Gamma (formally Brazilian origin, P.1, B.1.1.28) variants [19, 64] whilst the ever-changing variant landscape continues to be closely monitored as part of global surveillance efforts [66]. Currently, alternative authorized mAbs are available and are expected to retain activity against the Gamma and Beta variants [66]. Despite initial concerns regarding the Epsilon variant (formally California origin, B.1.429/B.1.427), recent pseudovirus neutralization data indicated that bamlanivimab together with etesevimab has only slightly reduced activity against the B.1.427/B.1.429 lineages or the L452R substitution found in this lineage [19]. Importantly, bamlanivimab and etesevimab together maintain potency against the Alpha variant (formally UK origin, B.1.1.7) as well as the rapidly spreading Delta variant (formally Indian origin, B.1.617.2) [60, 67].

Neutralizing mAbs should be used on the basis of an assessment of the risk-to-benefit ratio, access, and variant situation in each specific case. Since there is the potential risk for treatment failure due to viral variants that are resistant to bamlanivimab, etesevimab, or other mAbs, it remains critical that HCPs only consider authorized mAbs that are expected to retain activity against the most common circulating viral variants in their area and to refer to the most updated factsheet in their countries.

Conclusions

As widespread vaccination campaigns gather pace and society moves towards ending the COVID-19 pandemic and eventual herd immunity, neutralizing monoclonal antibodies such as bamlanivimab and etesevimab continue to provide critical treatment options that can reduce the morbidity and mortality in high-risk patient groups. In response to the unprecedented global spread of COVID-19, bamlanivimab and etesevimab were developed rapidly and EUAs were granted within months of initiating trials. This review article shares the iterative learnings gathered during the trials of bamlanivimab and etesevimab and addresses the most frequent questions received from HCPs and patients regarding indicated population, dose, use with other medications and vaccines, duration of protection, and emerging variants. The prevalence of variants or mutations can differ from state to state and by country, and there is growing evidence to support that combinations of antibodies are less susceptible to viral resistance. It remains critical that HCPs only consider authorized mAbs that are expected to retain activity against most common circulating viral variants in their area and to refer to the most updated authorization factsheet in their countries and local jurisdictions. Finally, a summary is provided of the practical learnings provided by independent organizations who adapted procedures and facilities in an effort to rapidly operationalize infusions of these mAbs. Real-world evidence substantiating the efficacy and safety of these mAbs is also discussed. It is important to note, however, that this is a narrative style review rather than a systematic review and intends to provide HCPs with a comprehensive understanding of how to identify the role of mAbs for ambulatory, high-risk patients, and all of the clinical practicalities involved with administering bamlanivimab and etesevimab in the context of vaccines and variants. Open queries such as biomarkers of response and long-term benefit are still pending. Real-world studies, such as OPTIMISE-C19, will be critical in providing information on the long-term efficacy to prevent hospitalizations and mortality within the subgroups of high-risk patients as well as sustained symptomology resolution of monoclonal antibodies [68].